Abstract
Breast cancer is the most common female cancer. Despite advances in prevention, early diagnosis, and surgical treatment, its prognosis is still poor. Therefore, immunological and pharmacological methods of treatment have been emphasized recently. Prominent targets of drugs or antibodies are proteins, which are predominantly expressed on breast cancer cells and are simultaneously involved in promoting cell growth or apoptosis. However, breast cancer is a heterogeneous disease, because breast cancer cells may show a variety of malignant gene expression patterns. Therefore, it is difficult at the current state of technology, to apply the optimal cocktail of drugs to hit all cancer cells of any given patient.
Under these circumstances, the option of targeting more tractable, normal cells surrounding the tumor instead of the less heterogeneous ones, preventing them from supporting tumor cell growth, became particularly interesting. Endothelial cells are important supporters of cancer cell growth. As a rule, tumors induce them to grow out and to develop a tumor vasculature, which enables the cancer cells to survive and to spread. The introduction of inhibitors of neovascularization was therefore an important milestone on the way toward treating breast cancer more successfully. It has already been demonstrated that the blockade of vascular endothelial growth results in regression of the disease and first clinical studies seemed to hint toward a beneficial effect on prolongation of survival. Nevertheless, more clinical and basic research is necessary to improve this therapy approach.
This review will compile the knowledge about recently developed anti-angiogenic drugs in the treatment of breast cancer and will provide an overview on currently relevant clinical trials
Keywords: Breast cancer, angiogenesis, vascular endothelial growth factor, tyrosine kinase inhibitor, neoangiogenesis inhibition, prognosis, tumor cell growth, Endothelial cells, anti-angiogenic drugs, clinical trials.
Current Pharmaceutical Design
Title:Target-based Anti-angiogenic Therapy in Breast Cancer
Volume: 18 Issue: 27
Author(s): Markus Wehland, Johann Bauer, Manfred Infanger and Daniela Grimm
Affiliation:
Keywords: Breast cancer, angiogenesis, vascular endothelial growth factor, tyrosine kinase inhibitor, neoangiogenesis inhibition, prognosis, tumor cell growth, Endothelial cells, anti-angiogenic drugs, clinical trials.
Abstract: Breast cancer is the most common female cancer. Despite advances in prevention, early diagnosis, and surgical treatment, its prognosis is still poor. Therefore, immunological and pharmacological methods of treatment have been emphasized recently. Prominent targets of drugs or antibodies are proteins, which are predominantly expressed on breast cancer cells and are simultaneously involved in promoting cell growth or apoptosis. However, breast cancer is a heterogeneous disease, because breast cancer cells may show a variety of malignant gene expression patterns. Therefore, it is difficult at the current state of technology, to apply the optimal cocktail of drugs to hit all cancer cells of any given patient.
Under these circumstances, the option of targeting more tractable, normal cells surrounding the tumor instead of the less heterogeneous ones, preventing them from supporting tumor cell growth, became particularly interesting. Endothelial cells are important supporters of cancer cell growth. As a rule, tumors induce them to grow out and to develop a tumor vasculature, which enables the cancer cells to survive and to spread. The introduction of inhibitors of neovascularization was therefore an important milestone on the way toward treating breast cancer more successfully. It has already been demonstrated that the blockade of vascular endothelial growth results in regression of the disease and first clinical studies seemed to hint toward a beneficial effect on prolongation of survival. Nevertheless, more clinical and basic research is necessary to improve this therapy approach.
This review will compile the knowledge about recently developed anti-angiogenic drugs in the treatment of breast cancer and will provide an overview on currently relevant clinical trials
Export Options
About this article
Cite this article as:
Wehland Markus, Bauer Johann, Infanger Manfred and Grimm Daniela, Target-based Anti-angiogenic Therapy in Breast Cancer, Current Pharmaceutical Design 2012; 18 (27) . https://dx.doi.org/10.2174/138161212802430468
DOI https://dx.doi.org/10.2174/138161212802430468 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
High Therapeutic Potential for Systemic Delivery of a Liposomeconjugated Herpes Simplex Virus
Current Cancer Drug Targets Inhibitors of the Immunoproteasome: Current Status and Future Directions
Current Pharmaceutical Design The PI3K/AKT/mTOR-Signal Transduction Pathway as Drug Target in Triple-Negative Breast Cancer
Clinical Cancer Drugs Genetic and Epigenetic Signatures in Human Hepatocellular Carcinoma:A Systematic Review
Current Genomics Molecular Modelling of Berberine Derivatives as Inhibitors of Human Smoothened Receptor and Hedgehog Signalling Pathway Using a Newly Developed Algorithm on Anti-Cancer Drugs
Recent Patents on Anti-Cancer Drug Discovery Radionuclide Molecular Imaging Using Affibody Molecules
Current Pharmaceutical Biotechnology Adrenomedullin as a Potential Therapeutic Agent for Inflammatory Bowel Disease
Current Protein & Peptide Science Small Molecule CXCR4 Chemokine Receptor Antagonists: Developing Drug Candidates
Current Medicinal Chemistry Patent Selections
Recent Patents on Anti-Cancer Drug Discovery The Origin of Lentivirus Research: Maedi-Visna Virus
Current HIV Research Tubulins as Therapeutic Targets in Cancer: from Bench to Bedside
Current Pharmaceutical Design The Exploitation of Toll-like Receptor 3 Signaling in Cancer Therapy
Current Pharmaceutical Design Telomere Shortening Is a Sole Mechanism of Aging in Mammals
Current Aging Science Potential Association Between TLR4 and Chitinase 3-Like 1 (CHI3L1/YKL-40) Signaling on Colonic Epithelial Cells in Inflammatory Bowel Disease and Colitis-Associated Cancer
Current Molecular Medicine Basic and Clinical Research Against Advanced Glycation End Products (AGEs): New Compounds to Tackle Cardiovascular Disease and Diabetic Complications
Recent Advances in Cardiovascular Drug Discovery (Discontinued) The Gene Expression Profiles of Medulloblastoma Cell Lines Resistant to Preactivated Cyclophosphamide
Current Cancer Drug Targets Biomarkers, Critical Disease Pathways, Drug Targets, and Alternative Medicine in Male Breast Cancer
Current Drug Targets Treatment of High-Grade Pelvic-Type Serous Carcinomas (Ovary, Fallopian Tube and Peritoneum): Current Therapeutic Paradigms, Prospects, and Challenges
Current Cancer Therapy Reviews Editorial Review (Thematic Issue: An Update on Central Sensitivity Syndromes and the Issues of Nosology and Psychobiology)
Current Rheumatology Reviews Lipoxygenase Inhibitors as Cancer Chemopreventives: Discovery, Recent Developments and Future Perspectives
Current Medicinal Chemistry